» Articles » PMID: 18770079

Methadone Maintenance Vs. Methadone Taper During Pregnancy: Maternal and Neonatal Outcomes

Overview
Journal Am J Addict
Specialty Psychiatry
Date 2008 Sep 5
PMID 18770079
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

This study compared five groups of participants: those receiving either three-day methadone-assisted withdrawal (MAW) alone (n = 67), three-day MAW followed by methadone maintenance (MM) (n = 8), seven-day MAW alone (n = 28), seven-day MAW followed by MM (n = 20), or a continuous MM sample (n = 52) enrolled between 1995-2001 in an urban drug treatment center. On average, patients in the three MM groups remained in treatment longer, attended more obstetrical visits, and more often delivered at the program hospital than patients in the two MAW alone groups. Given the poor maternal MAW outcomes, methadone maintenance should be considered as the primary treatment approach for opioid-dependent pregnant women.

Citing Articles

Outpatient tapering of buprenorphine in opioid use disorder pregnancies may improve neonatal outcomes.

Shah D, Adelli R, Chroust A, Lewis N, Olsen M J Perinatol. 2025; .

PMID: 39929991 DOI: 10.1038/s41372-025-02211-6.


Opioid Medical Detoxification Compared to Opioid Agonist Treatment during Pregnancy: A Scoping Review.

Ordean A, DeVuono I Healthcare (Basel). 2024; 12(13).

PMID: 38998804 PMC: 11240956. DOI: 10.3390/healthcare12131270.


The Psychiatrist's Role in Treating Perinatal Opioid Use Disorder and Reducing Maternal Mortality.

Witcraft S, Johnson C, Guille C Focus (Am Psychiatr Publ). 2024; 22(1):25-34.

PMID: 38694152 PMC: 11058912. DOI: 10.1176/appi.focus.20230018.


Timing of treatment for opioid use disorder among birthing people.

Kim K, Liu G, Dick A, Choi S, Agbese E, Corr T J Subst Use Addict Treat. 2024; 161:209289.

PMID: 38272119 PMC: 11090704. DOI: 10.1016/j.josat.2024.209289.


Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080 MOMs study.

Kropp F, Smid M, Lofwall M, Wachman E, Martin P, Murphy S J Subst Use Addict Treat. 2023; 149:209030.

PMID: 37023858 PMC: 10249488. DOI: 10.1016/j.josat.2023.209030.